Yale develops new animal model for hemophilia A

Researchers at Yale School of Medicine have developed a new animal model for studying hemophilia A, with the goal of eventually treating people with the disorder. Hemophilia A, a hereditary defect that prevents blood from clotting normally, is caused by a variety of mutations in the factor VIII gene.

Published online in the Journal of Thrombosis and Haemostasis, the study aimed to provide a better understanding of hemophilia A, according to first author and veterinarian Carmen Jane Booth, assistant professor of comparative medicine, and co-director of Mouse Research Pathology at Yale School of Medicine.

Booth and her team studied an inbred colony of rats that lived healthily for many years before spontaneously exhibiting symptoms similar to those of humans with hemophilia A, including hemorrhage, spontaneous bruising, swollen joints, prolonged bleeding from minor wounds and unexplained deaths among pregnant and postpartum rats. The team ruled out environmental factors as being responsible for the bleeding disorder in these rats, showed that it was inherited, and conducted diagnostic tests to identify the specific coagulation factor and underlying genetic defect responsible for the disorder.

The team found that the affected animals had a decreased amount of factor VIII. They sequenced the rat factor VIII cDNA and identified a mutation in this gene that was similar to mutations in some people with severe hemophilia. The factor VIII gene is located on chromosome 18 in rats, in contrast to its location on the X chromosome in mice and humans. “The larger size of the rat and the gene location difference makes the rat a unique model, well suited to developing novel therapies for acquired and hereditary factor VIII deficiencies,” said Booth.

When we get a minor cut, bleeding should stop in about 20 to 30 seconds, but in hemophiliacs, the bleeding is prolonged because the blood cannot form or maintain a proper blood clot. This can lead to bruises, injured joints and even life-threatening bleeding from everyday activities. The research team found that treating the affected rats with human recombinant factor VIII corrected their coagulation abnormality and stopped the prolonged bleeding.

“This is the only spontaneous rat model of hemophilia A,” said Booth. “Rats bruise and bleed similarly to humans with hemophilia A. Ultimately, we plan to translate this model for use in developing gene therapies and evaluating novel therapeutics for treating people with hemophilia A.”

Other authors on the study included veterinarian Marjory B. Brooks, and Sara Rockwell, James W. Murphy, Henry M. Rinder, M.D., Daniel Zelterman, Michael J. Paidas, M.D., Susan R. Compton and Peter W. Marks, M.D.

Citation: Journal of Thrombosis and Haemostatis doi: 10.1111/j. 1538-7836.2010.03978


Substack subscription form sign up

1 thought on “Yale develops new animal model for hemophilia A”

  1. ” Lohith Sindhe is a business owner born in Bangalore, India in 1981.Suffering from severe Hemophilia Factor VIII deficiency < 1%. He graduated from Bangalore University in 2002 with a Bachelor of Commerce degree.

    Lohith Sindhe is the co founder of the Sumne's Enterprises, which includes website designing,advertising,Stock Market trading & Stock Market Analysis.

    Lohith spent his childhood in lot of misery at age 5th got whole blood transfusion due to tooth gum bleeding. Again at age 8 got whole blood transfusion due to getting hurt in an minor accident.Somehow his parents managed to get out of these situations even though frequently he would get pain in joints. Hemophilia left him nearly 60% physically handicapped.

    Lohith however with a fighting spirit fougt back all these odd situations with the medicine i.e. Crayo Presipetate, whenever his condition worsened he use to take FACTORs and get away with it. You know these FACTORS are really costly.

    Lohith one day got introduced to homoeopathy treatment. His life has changed far better now compared to his past. He is now happily living with his wife and his new born baby. Last 1 Year and 7 Months has changed his life he takes homoepathy medicines regurarly i.e. in morning and evening after food. Now even though if there is any joints bleed, he can resist for 3 to 4 days and get back to normal without taking any more FACTORS. Surprisingly his resistence power is increasing and definetely one day he may well get rid of this hemophilia.

    Lohith can be reached by email at "[email protected]" for more details about the Homoepathy treatment. He is happy to guide and help millions of people around the globe who are suffering from Hemophilia. He aims to eradicate this disease as soon as possible. "

Comments are closed.